EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors

Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon und 2 weitere

Rheumatology and Therapy · 2026-02 · 13 (1) · 115-134

DOI: 10.1007/s40744-025-00804-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 14.11.2025. Verfasst von Philip J Mease und 13 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Research, Providence Swedish Medical Center, Nordstrom Medical Tower, 1229 Madison St, Suite 1450, Seattle, WA, 98104, USA. pmease@phili…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: There is limited prior literature comparing long-term treatment persistence between guselkumab and subcutaneous (SC) tumor necrosis factor inhibitors (TNFi) in biologic-naïve and biologic-experienced patients with active psoriatic arthritis (PsA). This study compared on-label persistence through 24 months between patients with active PsA newly initiating guselkumab or SC TNFi. METHODS: IQVIA PharMetrics® Plus database was used to identify adults with active PsA initiating guselkumab or an SC TNFi (adalimumab or biosimilar, certolizumab pegol, etanercept or biosimilar, SC golimumab) between 07/14/2020 and 12/31/2022 (index date: first treatment claim for one of these medications). Patients were further stratified as biologic-naïve (no pre-index biologic disease-modifying antirheumatic drug [bDMARD] claim) or biologic-experienced (≥ 1 pre-index bDMARD claim). The guselkumab and SC TNFi cohorts were balanced using overlap propensity score weighting. Treatment persistence with on-label therapy (absence of dose modification or therapy exposure gap of twice the duration between consecutive administrations, i.e., 112 days for guselkumab or 56 days for SC TNFi) was estimated using weighted Kaplan-Meier analysis through 24 months. On-label persistence rates were compared between cohorts using weighted Cox proportional hazards models. RESULTS: In the guselkumab cohort (N = 804), 361 (44.9%) were biologic-naïve and 443 (55.1%) were biologic-experienced; in the SC TNFi cohort (N = 2490), 2171 (87.2%) were biologic-naïve and 319 (12.8%) were biologic-experienced. At 24 months post index, on-label persistence rates were 45.5% (guselkumab) versus 28.5% (SC TNFi; P < 0.001). Patients initiating guselkumab were 2.24 times more likely to be persistent with on-label therapy through 24 months than patients initiating an SC TNFi (hazard ratio [95% confidence interval] 2.24 [1.90, 2.64]; P < 0.001). Results were consistent among biologic-naïve (2.36 [1.88, 2.98]; P < 0.001) and biologic-experienced patients (1.86 [1.46, 2.37]; P < 0.001). CONCLUSION: Patients with active PsA initiating guselkumab were significantly (approximately two times) more likely to remain persistent with on-label therapy through 24 months versus SC TNFi, overall and among biologic-naïve and biologic-experienced subgroups.

Schlagwörter

Stichwörter der Autor:innen

Biologic-experiencedBiologic-naïveGuselkumabPsoriatic arthritisSubcutaneous tumor necrosis factor inhibitorTreatment persistence

Autor:innen und Institutionen

  • Rheumatology Research, Providence Swedish Medical Center, Nordstrom Medical Tower, 1229 Madison St, Suite 1450, Seattle, WA, 98104, USA. pmease@philipmease.com.
  • University of Washington School of Medicine, Seattle, WA, USA. pmease@philipmease.com.
  • Salt Lake City Veterans Affairs Health, Salt Lake City, UT, USA.
  • University of Utah Health, Salt Lake City, UT, USA.
  • Johnson & Johnson, Horsham, PA, USA.
  • Drexel University College of Medicine, Philadelphia, PA, USA.

Förderung

  • Johnson and Johnson

Zitieren

APA

Mease, P. J., Walsh, J. A., Fitzgerald, T. P., Chakravarty, S. D., Adamson, E., Emond, B., Rossi, C., Schwartzbein, S., Yokoji, K., Wang, Y., Lefebvre, P., Pilon, D., Singla, S., & Merola, J. F. (2026). On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors. Rheumatology and Therapy, 13(1), 115-134. https://doi.org/10.1007/s40744-025-00804-3

Vancouver

Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, et al. On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors. Rheumatology and Therapy. 2026;13(1):115-134. doi:10.1007/s40744-025-00804-3

BibTeX
@article{Mease2026,
  author = {Mease, Philip J and Walsh, Jessica A and Fitzgerald, Timothy P and Chakravarty, Soumya D and Adamson, Elizabeth and Emond, Bruno and Rossi, Carmine and Schwartzbein, Samuel and Yokoji, Kana and Wang, Yuxi and Lefebvre, Patrick and Pilon, Dominic and Singla, Shikha and Merola, Joseph F},
  title = {On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors},
  journal = {Rheumatology and Therapy},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {115--134},
  doi = {10.1007/s40744-025-00804-3}
}
Kostenlos starten →